We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

Krka

Pharmaceutical > Slovenia > Krka
Change Company
Krka

Krka dd Novo Mesto is a Slovenia-based company involved in the production and sale of prescription pharmaceuticals, non-prescription products and animal health products. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing

Read more »
Krka dd Novo Mesto is a Slovenia-based company involved in the production and sale of prescription pharmaceuticals, non-prescription products and animal health products. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services. Krka sells approximately 92% of its products in more than 70 countries worldwide, mainly in Central and Eastern Europe

Buy all financials of Krka

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

income statement

Sales EUR mil
Gross Profit EUR mil
EBIT EUR mil
Net Profit EUR mil
ROE %
EBIT Margin %
Net Margin %
Employees
                  953 1,010 1,076 1,143 1,201    
                  583 625 659 676 712    
                  155 211 213 190 228    
                  174 171 163 160 173    
                  20.4% 17.3% 14.8% 13.4% 13.4%    
                  16.3% 20.9% 19.8% 16.7% 19.0%    
                  18.2% 16.9% 15.1% 14.0% 14.4%    
... ... ...             7,816 8,328 8,789 9,197 9,783    

balance sheet

                  1,341 1,488 1,534 1,627 1,760    
                  808 847 859 926 974    
                  533 642 675 701 786    
                  920 1,053 1,140 1,241 1,333    
                  421 435 394 386 427    
                  238 203 155 145 129    
                  183 232 239 241 298    
                  0.615 0.401 0.165 0.012 -0.209    
                  0.155 0.111 0.043 0.003 -0.050    
...                 3.02% 2.55% 3.04% 3.77% 200%    

cash flow

...                 160 178 244 278 303    
...                 -92.0 -113 -108 -167 -164    
...                 -61.8 -69.7 -124 -108 -93.7    
...                 5.81 -5.09 12.4 3.41 45.0    

valuation

                  3,098 2,823 2,294 2,216 2,930    
                  33.8 33.8 33.6 33.6 35.4    
                  64.0 63.0 52.7 50.0 60.0    
                  5.14 5.06 4.85 4.76 4.88    
                  27.2 31.2 33.9 36.9 37.6    
                  1.10 1.39 1.48 1.58 1.94   ...
                  12.4 12.4 10.9 10.5 12.3    
                  2.35 2.02 1.55 1.35 1.60    
                  1.72% 2.20% 2.81% 3.16% 3.23%   ...
...                 11.4% -1.57% -4.20% -1.77% 2.46%    
...                 17.5% 14.5% 8.90% 8.84% 1.83%    

Download Data
income statement Unit
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

income statement

Sales EUR mil
Cost of Goods & Services EUR mil
Gross Profit EUR mil
Staff Cost EUR mil
Other Cost EUR mil
EBITDA EUR mil
Depreciation EUR mil
EBIT EUR mil
Financing Cost EUR mil
Extraordinary Cost EUR mil
Pre-Tax Profit EUR mil
Tax EUR mil
Minorities EUR mil
Net Profit EUR mil
Dividends EUR mil
                  953 1,010 1,076 1,143 1,201    
                  370 385 417 468 489    
                  583 625 659 676 712    
...                 239 258 269 228 241    
...                 111 74.0 89.9 168 149    
                  232 292 300 280 322    
                  76.7 81.7 87.2 90.0 94.0    
                  155 211 213 190 228    
                  5.14 3.59 2.96 1.81 26.2    
                  -74.1 -4.26 9.78 -1.83 10.8    
                  224 211 200 190 190    
                  50.6 40.5 37.2 30.7 28.6    
                  -0.081 -0.107 -0.066 -0.076 -0.070    
                  174 171 163 160 173    
                  37.1 46.9 49.8 53.0 68.7   ...

growth rates

...                 0.328% 5.98% 6.50% 6.29% 5.03%    
... ...               13.6% -5.29% 8.08% 10.1% -1.35%    
...                 -26.6% 26.0% 2.56% -6.49% 14.7%    
...                 -36.5% 35.6% 0.957% -10.5% 19.5%    
...                 9.09% -5.77% -5.39% -4.74% 0.000%    
...                 11.4% -1.58% -4.81% -1.77% 8.08%    

ratios

                  20.4% 17.3% 14.8% 13.4% 13.4%    
...                 14.2% 13.0% 11.6% 11.1% 11.7%    
                  61.2% 61.8% 61.3% 59.1% 59.3%    
                  24.3% 29.0% 27.9% 24.5% 26.8%    
                  16.3% 20.9% 19.8% 16.7% 19.0%    
                  18.2% 16.9% 15.1% 14.0% 14.4%    
                  21.3% 27.4% 30.6% 33.1% 39.8%   ...
...                 3.02% 2.55% 3.04% 3.77% 200%    
                  0.615 0.401 0.165 0.012 -0.209    

Download Data
balance sheet Unit
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

balance sheet

                  808 847 859 926 974    
                  649 686 703 772 824    
                  127 123 119 119 116    
                  533 642 675 701 786    
                  182 229 253 250 236    
                  335 403 400 372 430    
                  13.4 7.79 20.2 23.0 67.3    
                  1,341 1,488 1,534 1,627 1,760    
                  920 1,053 1,140 1,241 1,333    
                  1.68 1.58 1.51 1.44 1.37    
                  421 435 394 386 427    
                  238 203 155 145 129    
                  105 67.2 25.5 12.9 0.000    
... ... ... ... ... ... ... ... ... ... 19.5 18.1 15.3 12.9    
                  183 232 239 241 298    
                  51.1 57.9 44.1 13.4 0.000    
                  72.0 90.9 86.6 100 131    
... ... ... ... ... ... ... ... ... ... ... ... ... ...    
                  1,341 1,488 1,534 1,627 1,760    

growth rates

...                 5.51% 11.0% 3.08% 6.04% 8.18%    
...                 17.5% 14.4% 8.21% 8.84% 7.42%    
...                 -19.0% -17.8% -57.9% -93.4% -2,163%    
...                 -15.0% -19.9% -44.4% -62.3% -100% ...  

ratios

                  156 125 69.6 26.3 0.000    
                  143 117 49.4 3.26 -67.3    
                  445 541 566 522 535    
                  1,253 1,388 1,426 1,448 1,509    
                  0.155 0.111 0.043 0.003 -0.050    
...                 3.02% 2.55% 3.04% 3.77% 200%    

Download Data
cash flow Unit
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

cash flow

                  174 171 163 160 173    
                  76.7 81.7 87.2 90.0 94.0    
...                 -25.5 21.9 19.1 -15.9 49.1    
...                 -65.4 -96.6 -25.0 44.3 -13.2    
...                 160 178 244 278 303    
...                 -83.4 -108 -100 -145 -152    
...                 -8.54 -5.51 -7.80 -21.8 -12.4    
...                 -92.0 -113 -108 -167 -164    
...                 -37.1 -46.9 -49.8 -53.0 -68.7   ...
...                 -27.6 -31.1 -55.5 -43.3 -26.3    
...                 -61.8 -69.7 -124 -108 -93.7    
...                 5.81 -5.09 12.4 3.41 45.0    

ratios

                  128 146 136 119 131    
                  179 217 222 195 176    
                  71.0 86.1 75.8 78.1 97.9    
                  236 277 282 236 209    
                  250 253 250 250 267    
                  7.41 7.48 7.44 7.44 7.53    
                  8.63 8.42 7.08 6.72 7.97    
...                 67.6 64.6 136 111 139    
...                 3.03% 3.03% 8.26% 6.46% 6.28%    

Download Data
other data Unit
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

other data

ROA %
Gross Margin %
Employees
Cost Per Employee USD per month
Cost Per Employee (Local Currency) EUR per month
Staff Cost (As % Of Total Cost) %
Effective Tax Rate %
Enterprise Value (EV) USD mil
EV/EBITDA
EV/Capital Employed
EV/Sales
EV/EBIT
Domestic Sales EUR mil
Capital Expenditures (As % of Sales) %
Revenues From Abroad EUR mil
Revenues From Abroad (As % Of Total) %
Sales in Slovenia EUR mil
Sales in South-East Europe EUR mil
Sales in Eastern Europe EUR mil
Sales in Central Europe EUR mil
Sales in Western Europe & Overseas Markets EUR mil
Sales from Human Health Products EUR mil
Sales from Human Health Products (Prescription Pharmaceuticals) EUR mil
Sales from Human Health Products (Non-Prescription Products) EUR mil
Sales from Cosmetics EUR mil
Sales from Animal Health Products EUR mil
Sales from Health Resort & Tourist Services EUR mil
Sales from Products EUR mil
Sales From Services EUR mil
Sales from Material & Merchandise EUR mil
Prescription Pharmaceuticals - Cardiovascular System (As % of Sales) %
Prescription Pharmaceuticals - Alimentary Tract & Metabolism (As % of Sales) %
Prescription Pharmaceuticals - Central Nervous System (As % of Sales) %
Prescription Pharmaceuticals - Anti-Infectives (As % of Sales) %
Prescription Pharmaceuticals - Blood & Blood-Forming Organs (As % of Sales) %
Prescription Pharmaceuticals - Genito-Urinary System & Sex Hormones (As % of Sales) %
Non-Prescription Pharmaceuticals - Vitamins & Minerals (As % of Sales) %
Non-Prescription Pharmaceuticals - Improvements Cerebral & Peripheral Circulation (As % of Sales) %
Non-Prescription Pharmaceuticals - Cough & Cold Products (As % of Sales) %
Non-Prescription Pharmaceuticals - Sore Throat Products (As % of Sales) %
Non-Prescription Pharmaceuticals - Alimentary Tract & Metabolism (As % of Sales) %
Non-Prescription Pharmaceuticals - Analgetics (As % of Sales) %
Non-Prescription Pharmaceuticals - Hari & Scalp Treatment (As % of Sales) %
Non-Prescription Pharmaceuticals - Herbals (As % of Sales) %
Animal Health Pharmaceuticals - General Anti-Infectives For Good Producing Animals (As % of Sales) %
Animal Health Pharmaceuticals - Antiparasitics For Good Producing Animals (As % of Sales) %
Animal Health Pharmaceuticals - Other Products For Good Producing Animals (As % of Sales) %
                  13.3% 12.1% 10.8% 10.1% 10.2%    
                  61.2% 61.8% 61.3% 59.1% 59.3%    
... ... ...             7,816 8,328 8,789 9,197 9,783    
... ... ...             3,550 3,419 3,548 2,649 2,721    
... ... ...             2,552 2,584 2,552 2,064 2,049    
...                 30.0% 32.3% 31.2% 23.9% 24.7%    
                  22.6% 19.1% 18.6% 16.1% 15.0%    
                  3,303 2,979 2,358 2,220 2,837    
                  10.2 7.70 5.65 6.17 6.65    
                  1.84 1.62 1.28 1.16 1.36    
                  2.49 2.23 1.58 1.51 1.78    
                  15.3 10.7 7.97 9.08 9.39    
... ... ... ... ... ... ... ...   106 105 102 91.0 86.6    
...                 8.75% 10.7% 9.30% 12.7% 12.6%    
... ... ... ... ... ... ... ...   847 905 974 1,052 1,114    
... ... ... ... ... ... ... ...   88.9% 89.6% 90.5% 92.0% 92.8%    
... ...               106 105 102 91.0 86.6    
... ...               128 138 146 148 146    
... ...               226 265 285 354 428    
... ...               268 294 288 282 283    
... ...               225 209 254 268 258    
... ...               883 948 1,001 1,068 1,126    
... ...               794 830 887 945 981    
... ...               89.6 117 114 123 145    
... ...               7.33 ... ... ... ... ... ...
... ...               27.8 30.5 38.1 42.8 42.6    
... ...               33.2 30.8 34.8 31.9 30.5    
... ... ... ... ... ... ... ... ... ... 920 972 1,045 1,105    
... ... ... ... ... ... ... ... ... ... 34.4 40.9 32.9 33.0    
... ... ... ... ... ... ... ... ... ... 55.7 62.7 65.7 63.3    
... ... ... ... ... ... ... ...   44.0% 45.0% 45.0% 46.0% 48.7%    
... ... ... ... ... ... ... ...   17.0% 19.0% 19.0% 19.0% 16.6%    
... ... ... ... ... ... ... ...   14.0% 14.0% 17.0% 17.0% 15.4%    
... ... ... ... ... ... ... ...   11.0% 9.00% 8.00% 7.00% 6.90%    
... ... ... ... ... ... ... ...   9.00% 7.00% 5.00% 5.00% 5.20%    
... ... ... ... ... ... ... ...   2.00% 3.00% 2.00% 2.00% 2.10%    
... ... ... ... ... ... ... ...   30.0% 29.0% 23.0% 22.0% 24.1%    
... ... ... ... ... ... ... ... ... ... ... 19.0% 19.0% 19.6%    
... ... ... ... ... ... ... ...   19.0% 18.0% 15.0% 14.0% 13.2%    
... ... ... ... ... ... ... ... ... ... ... 14.0% 13.0% 12.9%    
... ... ... ... ... ... ... ...   10.0% 9.00% 12.0% 12.0% 12.3%    
... ... ... ... ... ... ... ...   7.00% 5.00% 8.00% 12.0% 12.2%    
... ... ... ... ... ... ... ... ... ... ... 3.00% 3.00% 2.30%   ...
... ... ... ... ... ... ... ...   ... ... ... ... ... ... ...
... ... ... ... ... ... ... ...   69.0% 67.0% 60.0% 56.0% 54.5%    
... ... ... ... ... ... ... ...   17.0% 19.0% 25.0% 29.0% 33.5%    
... ... ... ... ... ... ... ...   14.0% 14.0% 15.0% 15.0% 12.0%    

Download Data

KRKA in Numbers

May 16, 2016
KRKA in Numbers

This Statistical Dossier offers a summary of KRKA's performance between 2000 and 2015 on an annual basis. The report can be downloaded in Excel file format.

You will find here all the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in specific areas

Read more »

This Statistical Dossier offers a summary of KRKA's performance between 2000 and 2015 on an annual basis. The report can be downloaded in Excel file format.

You will find here all the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in specific areas of the Company's business, you find and download them at the Company's Corporate Profile.

If you want to see more reports about the Company, please, go to the Company's Reports Page.

Krka dd Novo Mesto is a Slovenia-based company involved in the production and sale of prescription pharmaceuticals, non-prescription products and animal health products. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services. Krka sells approximately 92% of its products in more than 70 countries worldwide, mainly in Central and Eastern Europe

Krka at a Glance

June 7, 2014
Krka at a Glance

Krka dd Novo Mesto is a Slovenia-based company involved in the production and sale of prescription pharmaceuticals, non-prescription products and animal health products. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases

Read more »

Krka dd Novo Mesto is a Slovenia-based company involved in the production and sale of prescription pharmaceuticals, non-prescription products and animal health products. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services. Krka sells approximately 92% of its products in more than 70 countries worldwide, mainly in Central and Eastern Europe.

This report offers a summary of the Company's performance in 2000-2013. You will find here all the key numbers from the Company's balance sheet, income statement and cash flow and main ratios related to the Company's business

Krka in Numbers

June 4, 2014
Krka in Numbers

Krka dd Novo Mesto is a Slovenia-based company involved in the production and sale of prescription pharmaceuticals, non-prescription products and animal health products. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases

Read more »

Krka dd Novo Mesto is a Slovenia-based company involved in the production and sale of prescription pharmaceuticals, non-prescription products and animal health products. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services. Krka sells approximately 92% of its products in more than 70 countries worldwide, mainly in Central and Eastern Europe.

This excel file offers a summary of the Company's performance in 2000-2013. You will find here all the key numbers from the Company's balance sheet, income statement and cash flow and main ratios related to the Company's business

Krka invested total of EUR 109 mil in 2015, down 41.8% when compared to the previous year. Historically, company's investments reached an all time high of EUR 187 mil in 2014 and an all time low of EUR 50.3 mil in 2002.

Read more »

Krka invested total of EUR 109 mil in 2015, down 41.8% when compared to the previous year. Historically, company's investments reached an all time high of EUR 187 mil in 2014 and an all time low of EUR 50.3 mil in 2002.

When compared to total sales, investments reached 9.35% in 2015, down from 15.7% seen in the previous year. This is compared to 11.9% seen on average in the last five years.

As far as Krka's peers are concerned, EUR 33,302 mil and 9.12% at Gedeon Richter invested EUR 33,302 mil, or 9.12% of its sales in 2015. on 2015 numbers.

You can see all the company’s data at Krka Profile, or you can download a report on the company in the report section.

Krka - Indebtedness

March 19, 2018

Krka's net debt reached EUR -35.8 mil and accounted for -0.025 of equity at the end of 2015. The ratio is down 339% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of

Read more »

Krka's net debt reached EUR -35.8 mil and accounted for -0.025 of equity at the end of 2015. The ratio is down 339% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 0.225 in 2008 and an all time low of -0.050 in 2013.

When compared to EBITDA, net debt amounted to -0.117x at the end of the year. The ratio reached an all time high of 0.774 in 2001 and an all time low of -0.209 in 2013.

As far as Krka's peers are concerned, Gedeon Richter posted net debt to equity of -0.143x and -0.898x when compared to EBITDA at the end of 2015..

You can see all the company’s data at Krka Profile, or you can download a report on the company in the report section.

Krka's total assets reached EUR 1,809 mil at the end of 2015, up 8.14% when compared to the previous year.

Current assets amounted to EUR 823 mil, or 45.5% of total assets while cash reached EUR 35.8 mil at the end of 2015.

On

Read more »

Krka's total assets reached EUR 1,809 mil at the end of 2015, up 8.14% when compared to the previous year.

Current assets amounted to EUR 823 mil, or 45.5% of total assets while cash reached EUR 35.8 mil at the end of 2015.

On the other hand, total debt reached EUR 0.000 mil at the year-end, or 45.5% of total assets while firm's equity amounted to EUR 1,406 mil. As a result, net debt reached EUR -35.8 mil at the end of 2015 and accounted for -2.55% of equity.

You can see all the company’s data at Krka Profile, or you can download a report on the company in the report section.

Krka made a net profit of EUR 158 mil under revenues of EUR 1,165 mil in 2015, down -4.80% and -2.27%, respectively, when compared to the last year. This translates into a net margin of 13.6%.

Historically, the firm’s net

Read more »

Krka made a net profit of EUR 158 mil under revenues of EUR 1,165 mil in 2015, down -4.80% and -2.27%, respectively, when compared to the last year. This translates into a net margin of 13.6%.

Historically, the firm’s net profit reached an all time high of EUR 174 mil in 2009 and an all time low of EUR 27.6 mil in 2000. Since 2010, the firm's net profit has increased -7.47% or -1.54% a year on average.

On the operating level, EBITDA reached EUR 307 mil, up -18.1% when compared to the previous year. Over the last five years, company's EBITDA has grown 0.960% a year on average.

As far as Krka's peers are concerned, Gedeon Richter posted net and EBITDA margin of 14.9% and 27.0%, respectively in 2015.

You can see all the company’s data at Krka Profile, or you can download a report on the company in the report section.

See all charts of the company »
Krka's employees rose 2.41% to 10,532 in 2015
Krka's net profit fell 4.80% to EUR 158 mil in 2015
Krka's net profit fell 4.80% to EUR 158 mil in 2015
Krka's price/earnings (P/E) rose 14.9% to 13.5 in 2015
Krka's Net Debt/EBITDA fell 403% to -0.117 in 2015
Krka's Cash & Cash Equivalents rose 51.9% to EUR 35.8 mil in 2015
Krka's ROCE fell 7.17% to 9.90% in 2015
Krka's Capital Expenditures fell 41.8% to EUR 109 mil in 2015
Krka's Net Margin fell 2.59% to 13.6% in 2015
Krka's Share Price fell 0.667% to EUR 59.6 in 2014